产品
编 号：F447692
分子式：C23H36N6O5S
分子量：508.63
分子式：C23H36N6O5S
分子量：508.63
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 74863-84-6
产品详情
生物活性：
Argatroban (MD-805) is a direct, selective thrombin inhibitor.
体内研究：
Argatroban 可用于动物建模，构建内源性肠栓模型。肝切除大鼠的曲线下面积值、分布和消除半衰期显着增加。Argatroban 在肾脏中从 21-(R) 转化为 21-(S) 非对映异构体。21-(S) 非对映异构体比 R 同工型具有更高的抗血栓活性，并且该 21-(S) 异构体可能会优先被肝脏消除。1. 诱导溶栓致病原理Argatroban 是一种特异性凝血酶抑制剂，通过抑制动物凝血酶活性来建立溶栓模型。 具体造模方法Rat: Wistar ST • male • 8-week-old 8Administration: 2 mg/kg/h • iv • 1 hNote溶栓实验前应让大鼠随意饮水并禁食过夜。造模成功指标•血栓溶解的相对速率 ↓相关产品 Tranexamic acid (HY-B0149)拮抗产品
体外研究：
Argatroban (MD-805) may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of Argatroban (MD-805) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries. Argatroban (MD-805), as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban.
Argatroban (MD-805) is a direct, selective thrombin inhibitor.
体内研究：
Argatroban 可用于动物建模，构建内源性肠栓模型。肝切除大鼠的曲线下面积值、分布和消除半衰期显着增加。Argatroban 在肾脏中从 21-(R) 转化为 21-(S) 非对映异构体。21-(S) 非对映异构体比 R 同工型具有更高的抗血栓活性，并且该 21-(S) 异构体可能会优先被肝脏消除。1. 诱导溶栓致病原理Argatroban 是一种特异性凝血酶抑制剂，通过抑制动物凝血酶活性来建立溶栓模型。 具体造模方法Rat: Wistar ST • male • 8-week-old 8Administration: 2 mg/kg/h • iv • 1 hNote溶栓实验前应让大鼠随意饮水并禁食过夜。造模成功指标•血栓溶解的相对速率 ↓相关产品 Tranexamic acid (HY-B0149)拮抗产品
体外研究：
Argatroban (MD-805) may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of Argatroban (MD-805) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries. Argatroban (MD-805), as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备